Tumor necrosis factor ligand superfamily member 11 (TNFSF11) (TNFSF11)

Tumor necrosis factor ligand superfamily member 11 (TNFSF11), widely known as RANKL, is a type II transmembrane protein that serves as a master regulator of bone metabolism and immune system development [1, 2, 7]. It is primarily produced by osteoblasts, osteocytes, and activated T-cells, and it exists in both membrane-bound and soluble forms [1, 4]. The protein's primary biological function is to bind to its cognate receptor, RANK, on the surface of osteoclast precursors, which triggers a signaling cascade leading to the differentiation, activation, and survival of mature bone-resorbing osteoclasts [1, 2, 8]. This RANK/RANKL signaling axis is essential for maintaining skeletal integrity, but its overactivation is a hallmark of pathological bone loss in diseases such as postmenopausal osteoporosis, rheumatoid arthritis, and bone metastases [2, 7]. In clinical practice, TNFSF11 is a major therapeutic target, most notably for the monoclonal antibody denosumab, which acts as a high-affinity inhibitor by preventing RANKL from binding to RANK [7, 8]. This inhibition effectively reduces osteoclast activity, thereby increasing bone mineral density and reducing the risk of skeletal-related events in cancer patients [7]. Beyond its skeletal roles, TNFSF11 is involved in lymph node organogenesis and the regulation of T-cell-dependent immune responses, highlighting its importance at the intersection of bone and immune biology [3, 6]. Therapeutic modulation of this target requires careful monitoring for safety concerns such as hypocalcemia and osteonecrosis of the jaw, as well as potential immune-related side effects [10, 11].

Other names

RANKLReceptor activator of nuclear factor kappa-B ligandTRANCETNF-related activation-induced cytokineOPGLOsteoprotegerin ligandODFOsteoclast differentiation factorCD254TNLG6BOPTB2

Inhibition of TNFSF11 (RANKL) binding to its cognate receptor RANK, which prevents the differentiation, activation, and survival of bone-resorbing osteoclasts.